BRAF and melanoma: To address this unmet need, we synthesized a novel triphenylmethane, indolium 1, which has potent in vivo activity against LM36R (the counterpart of vemurafenib-sensitive LM36), which is an aggressive BRAF mutant melanoma that is vemurafenib-resistant [9,10,11].